| dc.description.abstract | Background: Canine skin and ear infections are common in small-animal practice and
increasingly complicated by multidrug resistance (MDR), yet data from Serbia are limited.
This study aimed to describe the bacterial etiology and antimicrobial resistance patterns
in canine otitis externa and pyoderma. Methods: We retrospectively reviewed laboratory
records from the Clinical Bacteriology and Mycology Laboratory, Faculty of Veterinary
Medicine, University of Belgrade (January 2017–August 2024). A total of 422 non-invasive
swabs from clinically ill dogs were included (ears: n = 210; skin: n = 212). Bacterial identification
used conventional methods and commercial systems, and disk-diffusion susceptibility
testing followed CLSI/EUCAST guidance. Methicillin resistance in staphylococci was assessed
by cefoxitin/oxacillin screening; MRSA was confirmed by PCR and PBP2a detection.
Resistance trends were compared between 2017–2020 and 2021–2024. Results: The leading
pathogens were Staphylococcus pseudintermedius (ears 48.1%; skin 79.7%) and Pseudomonas
aeruginosa (ears 29.1%; skin 7.6%). Staphylococci showed high resistance to macrolides, clindamycin,
tetracycline, and first-line β-lactams (amoxicillin–clavulanate, cephalexin), with
the highest susceptibilities to amikacin, florfenicol, and rifampicin. P. aeruginosa remained
most susceptible to amikacin, polymyxin B, and imipenem. Between the two periods,
S. pseudintermedius resistance increased to amikacin, fusidic acid, and cephalexin, while
resistance to florfenicol decreased. P. aeruginosa resistance to imipenem increased. The
prevalence of methicillin-resistant S. pseudintermedius (MRSP) was 27.4% (74/270). MDR
S. pseudintermedius and MDR P. aeruginosa were identified in 38.5% and 53.3% of isolates,
respectively. One isolate of each species was resistant to all tested drugs. Conclusions:
These findings confirm high levels of antimicrobial resistance in major canine skin and ear
pathogens and emphasize the need for susceptibility-based therapy, rational antimicrobial
use, and ongoing surveillance in small-animal practice. | en_US |